Organisation paid for research Program year 2025 Source: CMS Open Payments

Cedar Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$113,057

16 payments

Through program year 2025, Cedar Clinical Research is reported as receiving $113,057 in research payments, across 16 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $4,915 2
2024 Research $840 1
2023 Research $3,671 4
2022 Research $35,862 5
2021 Research $67,769 4

Breakdown

Who paid Research payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $66,269 3 payments
  2. ACADIA Pharmaceuticals Inc $11,300 3 payments
  3. Avanir Pharmaceuticals, Inc. $10,375 3 payments
  4. Otsuka Pharmaceutical Development & Commercialization, Inc. $10,187 2 payments
  5. Supernus Pharmaceuticals, Inc. $9,171 2 payments
  6. AbbVie, Inc. $3,255 2 payments
  7. BioXcel Therapeutics, Inc. $2,500 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $66,269 3 payments
  2. Acp-103-069 $11,300 3 payments
  3. 18-Avp-786-207 $10,375 3 payments
  4. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Avp-786 (Deudextromethorphan Hydrobromide [D6-Dm]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (Tbi) $10,187 2 payments
  5. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NV-5138 in Adults With Treatment Resistant Depression $9,171 2 payments
  6. Bxcl501401 $2,500 1 payment
  7. A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder $2,415 1 payment
  8. A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder $840 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record